Status:
COMPLETED
Reflux Esophagitis Phase III Study (Initial Treatment)
Lead Sponsor:
AstraZeneca
Conditions:
Reflux Esophagitis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omepraz...
Eligibility Criteria
Inclusion
- Endoscopically verified Reflux Esophagitis classified into Los Angeles classification Grade A, B, C or D within 1 week before randomisation
Exclusion
- Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation.
- Use of any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
602 Patients enrolled
Trial Details
Trial ID
NCT00633932
Start Date
December 1 2007
End Date
December 1 2008
Last Update
December 20 2010
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Akita, Akita, Japan
2
Research Site
Kashiwa, Chiba, Japan
3
Research Site
Kisarazu, Chiba, Japan
4
Research Site
Kōriyama, Fukishima, Japan